AccrualNet: A New NCI Online Resource to Support Clinical Trial Patient Accrual
The National Cancer Institute announced the launch of a new online resource, AccrualNet, in response to needs expressed by clinical trials professionals and investigators. Despite dedicated clinical trial recruitment efforts, successful accrual remains a challenge - only 3-5% of potentially eligible cancer patients enroll in clinical trials. AccrualNet is designed for practicing professionals to support clinical trial accrual needs. The Web site is a repository for literature and other resources and serves as a 'community of practice' to encourage dialog and discussion. AccrualNet includes:
- Linkable access to existing tools and materials your colleagues are using
- A searchable list of published journal articles on clinical trial recruitment
- A space to ask questions and share experiences and strategies
- Training opportunities available to orient and educate new staff to successful recruitment strategies
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.
